News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
279,298 Results
Type
Article (15125)
Company Profile (281)
Press Release (263892)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (81609)
Career Advice (168)
Deals (13531)
Drug Delivery (36)
Drug Development (52547)
Employer Resources (31)
FDA (6498)
Job Trends (5535)
News (149930)
Policy (10732)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (970)
Accelerated approval (2)
Adcomms (15)
Allergies (53)
Alliances (22122)
ALS (63)
Alzheimer's disease (857)
Antibody-drug conjugate (ADC) (99)
Approvals (6525)
Artificial intelligence (124)
Autoimmune disease (18)
Automation (5)
Bankruptcy (107)
Best Places to Work (4964)
BIOSECURE Act (7)
Biosimilars (49)
Biotechnology (232)
Bladder cancer (60)
Brain cancer (20)
Breast cancer (160)
Cancer (1462)
Cardiovascular disease (119)
Career advice (148)
Career pathing (2)
CAR-T (112)
Cell therapy (319)
Cervical cancer (10)
Clinical research (42904)
Collaboration (540)
Compensation (256)
Complete response letters (15)
COVID-19 (1111)
CRISPR (39)
C-suite (161)
Cystic fibrosis (88)
Data (1522)
Denatured (11)
Depression (30)
Diabetes (136)
Diagnostics (1425)
Digital health (4)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (86)
Drug pricing (28)
Drug shortages (4)
Duchenne muscular dystrophy (90)
Earnings (30936)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (49477)
Executive appointments (453)
FDA (7223)
Featured Employer (30)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (504)
Gene editing (94)
Generative AI (10)
Gene therapy (245)
GLP-1 (376)
Government (1185)
Grass and pollen (2)
Guidances (20)
Healthcare (6851)
Huntington's disease (22)
IgA nephropathy (23)
Immunology and inflammation (91)
Indications (20)
Infectious disease (1195)
Inflammatory bowel disease (123)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (66)
Interviews (18)
IPO (7421)
IRA (11)
Job creations (887)
Job search strategy (141)
Kidney cancer (7)
Labor market (5)
Layoffs (212)
Leadership (3)
Legal (1456)
Liver cancer (32)
Lung cancer (208)
Lymphoma (101)
Machine learning (3)
Management (7)
Manufacturing (139)
MASH (52)
Medical device (2858)
Medtech (2860)
Mergers & acquisitions (6436)
Metabolic disorders (390)
Multiple sclerosis (55)
NASH (13)
Neurodegenerative disease (64)
Neuropsychiatric disorders (26)
Neuroscience (1259)
NextGen: Class of 2025 (2090)
Non-profit (900)
Northern California (1691)
Now hiring (22)
Obesity (197)
Opinion (107)
Ovarian cancer (62)
Pain (42)
Pancreatic cancer (54)
Parkinson's disease (119)
Partnered (8)
Patents (131)
Patient recruitment (74)
Peanut (36)
People (25993)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14738)
Phase II (19590)
Phase III (13157)
Pipeline (809)
Policy (45)
Postmarket research (1017)
Preclinical (6187)
Press Release (30)
Prostate cancer (60)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (302)
Real estate (1450)
Recruiting (12)
Regulatory (9218)
Reports (16)
Research institute (983)
Resumes & cover letters (19)
Rett syndrome (4)
RNA editing (4)
RSV (25)
Schizophrenia (60)
Series A (98)
Series B (64)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1481)
Special edition (11)
Spinal muscular atrophy (118)
Sponsored (12)
Startups (2007)
State (1)
Stomach cancer (6)
Supply chain (24)
Tariffs (6)
The Weekly (36)
United States (13234)
Vaccines (252)
Venture capitalists (32)
Weight loss (112)
Women's health (15)
Worklife (2)
Date
Today (76)
Last 7 days (342)
Last 30 days (1460)
Last 365 days (20048)
2025 (5949)
2024 (21128)
2023 (23101)
2022 (27998)
2021 (29011)
2020 (24599)
2019 (17038)
2018 (12416)
2017 (14469)
2016 (12470)
2015 (15006)
2014 (10839)
2013 (7843)
2012 (7935)
2011 (7950)
2010 (7732)
Location
Africa (154)
Alabama (41)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17956)
Australia (3041)
California (3845)
Canada (1147)
China (348)
Colorado (147)
Connecticut (151)
Delaware (112)
Europe (38704)
Florida (461)
Georgia (126)
Idaho (17)
Illinois (227)
India (10)
Indiana (101)
Iowa (1)
Japan (81)
Kansas (61)
Kentucky (6)
Louisiana (3)
Maine (11)
Maryland (486)
Massachusetts (3013)
Michigan (72)
Minnesota (148)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (21)
New Hampshire (14)
New Jersey (998)
New Mexico (12)
New York (1038)
North Carolina (555)
North Dakota (4)
Northern California (1691)
Ohio (111)
Oklahoma (9)
Oregon (21)
Pennsylvania (735)
Puerto Rico (6)
Rhode Island (18)
South America (222)
South Carolina (4)
Southern California (1481)
Tennessee (26)
Texas (443)
Utah (54)
Virginia (76)
Washington D.C. (30)
Washington State (346)
Wisconsin (15)
279,298 Results for "tract therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
April 21, 2025
·
5 min read
Press Releases
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
April 1, 2025
·
1 min read
Press Releases
Paige Launches New System-Wide AI Application for the Gastrointestinal Tract
March 13, 2025
·
3 min read
Press Releases
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
April 2, 2025
·
9 min read
Press Releases
Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older
March 26, 2025
·
11 min read
Drug Development
Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Biliary Tract and Gastric Cancers at ASCO 2024
Bold Therapeutics announced positive Phase 2 safety and efficacy results for the company’s lead asset BOLD-100 in the treatment of advanced metastatic biliary tract cancer (BTC) and gastric cancer (GC) at the American Society of Clinical Oncology (ASCO) annual meeting.
June 3, 2024
·
3 min read
Press Releases
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
April 1, 2025
·
10 min read
FDA
Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections
Allecra Therapeutics, a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced that the U.S. Food and Drug Administration has approved EXBLIFEP®, as a treatment for complicated urinary tract infections, including pyelonephritis, in patients 18 years and older.
February 27, 2024
·
4 min read
Press Releases
Complicated Urinary Tract Infections (cUTIs) Market to Reach USD 3,090.7 Million by 2035, Impelled by Advancements in Antimicrobial Therapies
January 29, 2025
·
12 min read
FDA
FDA Approves New Treatment for Uncomplicated Urinary Tract Infections
Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
April 24, 2024
·
3 min read
1 of 27,930
Next
